Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates

被引:122
|
作者
Kuipers, ME
de Vries, HG
Eikelboom, MC
Meijer, DKF
Swart, PJ
机构
[1] Univ Groningen, Inst Drug Studies, Univ Ctr Pharm, Sect Pharmacokinet & Drug Delivery, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen Hosp, Sect Med Microbiol, NL-9713 GZ Groningen, Netherlands
关键词
D O I
10.1128/AAC.43.11.2635
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Because of the rising incidence of failures in the treatment of oropharyngeal candidosis in the case of severely immunosuppressed patients (mostly human immunodeficiency virus [HIV]-infected patients), there is need for the development of new, more effective agents and/or compounds that support the activity of the common antifungal agents. Since lactoferrin is one of the nonspecific host defense factors present in saliva that exhibit antifungal activity, we studied the antifungal effects of human, bovine, and iron-depleted lactoferrin in combination with fluconazole, amphotericin B, and 5-fluorocytosine in vitro against clinical isolates of Candida species. Distinct antifungal activities of lactoferrin were observed against clinical isolates of Candida. The MICs generally were determined to be in the range of 0.5 to 100 mg.ml(-1). Interestingly, in the combination experiments we observed pronounced cooperative activity against the growth of Candida by using lactoferrin and the three antifungals tested. Only in a limited concentration range was minor antagonism detected. The use of lactoferrin and fluconazole appeared to be the most successful combination. Significant reductions in the minimal effective concentrations of fluconazole were found when it was combined with a relatively low lactoferrin concentration (1 mg/ml). Such combinations still resulted in complete growth inhibition, while synergy of up to 50% against several Candida species was observed. It is concluded that the combined use of lactoferrin and antifungals against severe infections with Candida is an attractive therapeutic option. Since fluconazole-resistant Candida species have frequently been reported, especially in HIV infected patients, the addition of lactoferrin to the existing fluconazole therapy could postpone the occurrence of species resistance against fluconazole. Clinical studies to further elucidate the potential utility of this combination therapy have been initiated.
引用
收藏
页码:2635 / 2641
页数:7
相关论文
共 50 条
  • [1] In Vitro Antifungal Activity of Sertraline and Synergistic Effects in Combination with Antifungal Drugs against Planktonic Forms and Biofilms of Clinical Trichosporon asahii Isolates
    Cong, Lin
    Liao, Yong
    Yang, Suteng
    Yang, Rongya
    PLOS ONE, 2016, 11 (12):
  • [2] In Vitro Effects of Farnesol Alone and in Combination with Antifungal Drugs Against Aspergillus Clinical Isolates
    Onder, Sukran
    Oz, Yasemin
    MEDICAL MYCOLOGY JOURNAL, 2021, 62 (01) : 5 - 10
  • [3] Synergistic association of clioquinol with antifungal drugs against biofilm forms of clinical Fusarium isolates
    de Chaves, Magda Antunes
    do Amaral, Thais Ferreira
    da Silva Rodrigues Coutinho, Natalia Monteiro
    Andrzejewski Kaminski, Tais Fernanda
    Teixeira, Mario Lettieri
    Souza de Oliveira, Luis Flavio
    de Andrade, Saulo Fernandes
    Fuentefria, Alexandre Meneghello
    MYCOSES, 2020, 63 (10) : 1069 - 1082
  • [4] Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida -: Impact on the development of buccal preparations of lactoferrin
    Kuipers, ME
    Beljaars, L
    Van Beek, N
    De Vries, HG
    Heegsma, J
    Van Den Berg, JJM
    Meijer, DKF
    Swart, PJ
    APMIS, 2002, 110 (04) : 290 - 298
  • [5] Susceptibility of Candida spp. clinical isolates to antifungal drugs
    Tyski, S.
    Staniszewska, M.
    Rozbicka, B.
    Rajnisz, A.
    Bocian, E.
    Wasinska, E.
    Kurzatkowski, W.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S566 - S566
  • [6] Comparative in vitro activities of seven antifungal drugs against clinical isolates of Candida parapsilosis complex
    Khodavaisy, S.
    Badali, H.
    Meis, J. F.
    Modiri, M.
    Mahmoudi, S.
    Abtahi, H.
    Salehi, M.
    Manshadi, S. A. Dehghan
    Aala, F.
    Afshari, S. Agha Kuchak
    Lotfali, E.
    Ahangarkani, F.
    Rezaie, S.
    JOURNAL DE MYCOLOGIE MEDICALE, 2020, 30 (03):
  • [7] In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species
    Nishi, Isao
    Sunada, Atsuko
    Toyokawa, Masahiro
    Asari, Seishi
    Iwatani, Yoshinori
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2009, 15 (01) : 1 - 5
  • [8] Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical Candida glabrata and Candida krusei isolates
    Sharifzadeh, Aghil
    Khosravi, Ali Reza
    Shokri, Hojjatollah
    Tari, Paria Samadi
    MICROBIAL PATHOGENESIS, 2017, 107 : 390 - 396
  • [9] Susceptibility of clinical isolates from oral mucosa of Candida to antifungal drugs
    Dorocka-Bobkowska, B
    Byks, H
    JOURNAL OF DENTAL RESEARCH, 1998, 77 (05) : 1225 - 1225
  • [10] INVITRO COMPARISON OF CILOFUNGIN ALONE AND IN COMBINATION WITH OTHER ANTIFUNGAL AGENTS AGAINST CLINICAL ISOLATES OF CANDIDA SPECIES
    SMITH, KR
    LANK, KM
    DISMUKES, WE
    COBBS, CG
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (07) : 588 - 592